Peptide-Based Cardiovascular Therapeutics Market By Drug Type (Vasopeptides, Natriuretic Peptides, Endothelin Receptor Antagonists), By Application (Heart Failure, Hypertension, Atherosclerosis), By End-User (Hospitals & Clinics, Cardiovascular Research Centers, Pharmaceutical Companies), By Distribution Channel (Direct Sales, Distributors, Online Retailers), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Peptide-Based Cardiovascular Therapeutics Market was valued at USD 2.2 billion in 2024-e and will surpass USD 3.5 billion by 2030; growing at a CAGR of 8.0% during 2025 - 2030.

The peptide-based cardiovascular therapeutics market is expanding rapidly, fueled by the growing prevalence of cardiovascular diseases and the increasing adoption of innovative peptide therapies. Peptide-based drugs have shown significant promise in treating a wide range of cardiovascular conditions, including heart failure, hypertension, and atherosclerosis. Peptides offer several advantages, such as their ability to target specific receptors, modulate biochemical pathways more effectively, and potentially provide fewer side effects compared to traditional small-molecule drugs. This has led to increased interest from both pharmaceutical companies and research institutions in developing peptide-based therapies for cardiovascular applications.

One of the key drivers of market growth is the rising incidence of heart failure and other chronic cardiovascular conditions, which are becoming more prevalent due to aging populations and lifestyle factors such as poor diet and physical inactivity. Additionally, advancements in peptide drug design, including the development of more stable and bioavailable peptides, have enhanced their therapeutic potential. As a result, the peptide-based cardiovascular therapeutics market is poised for significant growth in the coming years, attracting attention from major pharmaceutical companies looking to expand their cardiovascular portfolios.

Vasopeptides Segment is Largest Owing to Broad Application in Cardiovascular Conditions

The vasopeptides segment is the largest in the peptide-based cardiovascular therapeutics market owing to their broad application in treating various cardiovascular conditions, particularly heart failure and hypertension. Vasopeptides are peptides that exert effects on blood vessels, helping to regulate blood pressure and improve cardiac function. These peptides typically work by acting on the vasculature to induce vasodilation, reduce blood pressure, and alleviate the symptoms associated with heart failure.

Vasopeptides have demonstrated efficacy in clinical trials, which has led to their increasing use in managing cardiovascular diseases. One of the most well-known examples of vasopeptides is the natriuretic peptides, which help control blood volume and pressure by promoting sodium excretion and vasodilation. Their ability to target multiple pathways makes them versatile and effective, positioning vasopeptides as the leading therapeutic class in the peptide-based cardiovascular therapeutics market.

Heart Failure Application is Fastest Growing Owing to Rising Prevalence and Treatment Advancements

The heart failure application segment is the fastest growing in the peptide-based cardiovascular therapeutics market, primarily driven by the rising prevalence of heart failure worldwide and the increasing demand for effective treatments. Heart failure is a chronic and progressive condition that affects millions of people globally, especially among the aging population. The management of heart failure often requires long-term treatment with drugs that can enhance cardiac output, reduce fluid retention, and alleviate symptoms.

Peptide-based therapies are gaining attention due to their potential to improve outcomes for heart failure patients. Vasopeptides, such as natriuretic peptides, have shown promising results in clinical trials for heart failure, leading to growing interest from both healthcare providers and pharmaceutical companies. As the global burden of heart failure continues to rise, the demand for innovative peptide therapies is expected to grow rapidly, making heart failure one of the fastest growing applications in this market.

Hospitals & Clinics Segment is Largest End-User Owing to Direct Patient Care

The hospitals and clinics segment is the largest end-user in the peptide-based cardiovascular therapeutics market due to their direct involvement in treating patients with complex cardiovascular conditions. Hospitals and clinics are the primary settings where patients with severe cardiovascular diseases, such as heart failure and hypertension, are diagnosed and treated. These healthcare institutions are equipped with the necessary infrastructure and expertise to administer peptide-based therapies, which often require specialized care and monitoring.

Additionally, hospitals and clinics are the main locations where peptide-based cardiovascular therapeutics are administered, either through intravenous infusions or injectable formulations. The widespread use of these drugs in hospitals and clinics is expected to continue driving the market's growth, as they remain the primary healthcare facilities for treating acute and chronic cardiovascular conditions.

North America is Largest Region Owing to Advanced Healthcare Infrastructure

North America is the largest region in the peptide-based cardiovascular therapeutics market, owing to its advanced healthcare infrastructure, high healthcare spending, and a large patient population suffering from cardiovascular diseases. The United States, in particular, has a high prevalence of cardiovascular diseases, including heart failure, hypertension, and atherosclerosis, which has contributed to the growing demand for effective treatments.

The region also benefits from a well-established pharmaceutical industry and significant research investments in developing new peptide therapies. Many of the leading global pharmaceutical companies, as well as cardiovascular research centers, are based in North America, driving both innovation and the commercialization of peptide-based cardiovascular therapeutics. As a result, North America remains the dominant region in the market.

Competitive Landscape

The peptide-based cardiovascular therapeutics market is highly competitive, with numerous pharmaceutical companies and biotechnology firms vying for market share. The market is characterized by a strong focus on research and development, as companies aim to discover and commercialize new peptide therapies that can effectively address cardiovascular diseases. Key players are focusing on improving the stability and bioavailability of peptides, as well as exploring combination therapies to enhance therapeutic outcomes.

In addition to large pharmaceutical companies, several smaller biotechnology firms are making significant strides in peptide drug development, particularly in the areas of heart failure and hypertension. The competitive landscape is driven by factors such as the efficacy of treatments, pricing strategies, and regulatory approvals. With ongoing advancements in peptide-based drug development and increasing collaboration between pharmaceutical companies and research centers, the competitive dynamics of the peptide-based cardiovascular therapeutics market are expected to evolve significantly in the near future.

List of Leading Companies:

• Novartis
• Roche
• Pfizer
• Merck & Co.
• Sanofi
• Amgen Inc.
• GlaxoSmithKline
• Eli Lilly and Company
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Boehringer Ingelheim
• AstraZeneca
• Bayer
• AbbVie
• Gilead Sciences

Recent Developments:

• In December 2024, Novartis launched a new vasopeptide-based therapy for heart failure patients.
• In November 2024, Roche received approval for its peptide-based drug for treating hypertension.
• In October 2024, Pfizer introduced a new peptide-based therapeutic for atherosclerosis management.
• In September 2024, Merck & Co. expanded its portfolio of peptide-based cardiovascular drugs for heart disease.
• In August 2024, Amgen Inc. announced a collaboration with a biotech firm to develop new peptide drugs for cardiovascular applications.XXXX

Report Scope: